新媒网 · 跨境数据社区

Discover how this Bio-Tech company is leveraging AI to potentially disrupt the $200 billion cancer treatment industry. Rakovina Therapeutics (TSX.V: RKV) is a Canadian biopharmaceutical company focused on developing innovative DNA-damage (DDR) response-based therapies for the treatment of cancer. Leveraging cutting-edge AI platforms, including Deep Docking and Variational AI's Enki platforms, to compress drug discovery timelines from years to months!! Targeting the DNA Damage Response (DDR) Market, projected to grow to $18 Billion annually by 2030. Led by a world-class Management team and advisory board including former AstraZeneca DDR program director Petra Hamerlik, Rakovina is set to hit it big in this growing market! The Deep Docking platform discovered a drug that was licensed to Roche Pharma in 2015 for over $140M USD! Discover Rakovina’s exclusive access to the Deep Docking AI Platform to rapidly screen billions of drug candidates against DNA-damage response targets. Click "Learn More" to explore further.